Physician Photo

Robert W. Yeh, MD, MBA

Co-Director, MGH Chronic Total Occlusion (CTO) Intervention Program

Interventional Cardiologist, MGH Cardiac Catheterization Laboratory

  • Phone: 617-643-7357
Department of Medicine


  • Critical Care Center
  • Cardiac Intensive Care Unit
  • Heart Center
  • Interventional Cardiology
Clinical Interests
Interventional cardiology
Acute coronary syndromes, Chest pain, Heart attacks
Transradial catheterization
Treatment of Chronic Totol Occlusions
Dissection Reetry and Retrograde CTO Methods
Boston: Massachusetts General Hospital
Medical Education
MD, Harvard Medical School
Residency, Massachusetts General Hospital
Fellowship, Massachusetts General Hospital
Fellowship, University of California San Francisco
Board Certifications
Internal Medicine, American Board of Internal Medicine
Cardiovascular Disease, American Board of Internal Medicine
Interventional Cardiology, American Board of Internal Medicine
Foreign Languages
Patient Age Group
Accepting New Patients

BiographyDr. Yeh is a graduate of Harvard Medical School, and has also received graduate degrees in health policy from the London School of Hygiene and Tropical Medicine/Economics (jointly) and business administration from Oxford University.  He completed residency at the MGH, cardiology fellowship at the University of California, San Francisco, and interventional cardiology fellowship at the MGH.  Dr. Yeh is a member of the interventional cardiology staff, focusing on coronary interventional procedures, including transradial catheterization and recanalization of chronic total occlusions (CTO).  He is the Co-Director of the MGH CTO Intervention Program, and specializes in complex coronary procedures involving retrograde and antegrade dissection-reentry techniques.

His research examines real world outcomes and the comparative effectiveness of novel cardiovascular devices and therapies, in collaboration with faculty at the Department of Health Care Policy at Harvard Medical School.  He also serves as Medical Director for Trial Design at the Harvard Clinical Research Institute, where he is involved in the design of clinical trials and post-marketing studies of cardiovascular devices.  Dr. Yeh's research is funded by a K23 career development award from the National Heart, Lung and Blood Institute, as well as the American Heart Association, the Harvard Clinical Research Institute, and the Hassenfeld Scholars Program.


View my most recent publications at PubMed

For a complete list, see PubMed link

Selected Publications:

Wasfy JH, Rosenfield K, Zelevinsky K, Sakhuja R,Lovett A, Spertus JA, Wimmer NJ, Mauri L, Normand SL, Yeh RW.  A Prediction Modelto Identify Patients at High Risk for 30-Day Readmission After PercutaneousCoronary Intervention.  Circulation:Cardiovascular Quality and Outcomes. 2013 Jul 1;6(4):429-35.

Amin AP, Spertus JA, Cohen DJ, Chhatriwalla A, Kennedy DF, Vilain K, Salisbury AC, Venkitachalam L, Lai SM, Mauri L, Normand ST, Rumsfeld J, Messenger JC, Yeh RW.  Use of drug-eluting stents as a function ofpredicted benefit: clinical and economic implications of current practice.  Archives of Internal Medicine.  2012 Aug 13:172(15):1145-52.

Yeh RW, Sidney S, Sorel M, Chandra M, Selby JV, Go AS.Population trends in the incidence and outcomes of acute myocardial infarction.The New England Journal of Medicine. 2010 June 10;362(23):2155-65.Yeh RW, Chandra M, McCulloch CE, Go AS.

In General for Dec. 16, 2011

In General awards and honors

Widening Geographic Disparities in Hospitalized Heart Attack Incidence and Outcome Rates

February is American Heart Month, and the spotlight is on heart health. Throughout this month, we will be featuring articles including discussions with physicians in the Massachusetts General Heart Center to learn more about the topics surrounding heart disease, the leading cause of death in the U.S. for both men and women.

Back on his feet, living angina-free:

New treatment option allows some coronary artery patients to "bypass" bypass surgery. Interventional cardiologists at the Institute for Heart, Vascular and Stroke Care at Mass General offer a less-invasive treatment with quicker recovery.

Choice to use drug-eluting stents has little relation to patients' probable benefit

A new study finds that the use of drug-eluting stents after angioplasty bears little relationship to patients' predicted risk of restenosis (reblockage) of the treated coronary artery, the situation the devices are designed to prevent.

Interventional Cardiology Associates
55 Fruit Street
Boston, MA 02114

Phone: 617-643-7357
Fax: 617-726-7437